Implications of five-year outcomes of COMMENCE (SAVR) trial for aortic valve surgery in China
- VernacularTitle:COMMENCE（SAVR）研究五年随访结果给中国主动脉瓣膜外科带来的思考
- Author:
Chunsheng WANG
1
;
Shuyang LU
1
Author Information
1. Department of Cardiovascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, P.R.China
- Publication Type:Journal Article
- Keywords:
Surgical aortic valve replacement (SAVR);
transcatheter aortic valve replacement (TAVR);
structural valve deterioration;
COMMENCE trial
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(08):877-883
- CountryChina
- Language:Chinese
-
Abstract:
The advent of transcatheter aortic valve replacement (TAVR) has brought up a new treatment option for patients with severe aortic valve disease. However, with the continuous expansion of surgical indications, problems such as structural valve deterioration caused by biological prosthesis have become increasingly prominent. In the newly announced 5-year follow-up results of COMMENCE (SAVR) trial, the aortic bioprosthesis using the new RESILIA biotissue material demonstrated extraordinary clinical safety, efficacy and durability with zero structural valve deterioration and excellent hemodynamic evaluation results. As a result, patients with valvular heart disease have more diverse therapeutic options. However, the choice between surgical aortic valve replacement (SAVR) and TAVR, biological prosthesis and mechanical prosthesis, etc, has become more and more prominent, which brings more difficulties to clinicians. This paper reviews the research background, 5-year follow-up results of COMMENCE trial and the implications for aortic valve surgery in China.
